LXR Agonist T0901317's Hepatic Impact Overrules Its Atheroprotective Action in Macrophages, Driving Early Atherogenesis in Chow-Diet-Fed Male Apolipoprotein E Knockout Mice

In conclusion, these findings highlight that the pro-atherogenic hepatic effects of LXR agonism are dominant over the anti-atherogenic effects in macrophages in determining the overall atherosclerosis outcome under low-fat diet feeding conditions. A low-fat diet experimental setting, as compared to the commonly used high-fat-diet-based preclinical setup, thus appears more sensitive in uncovering the potential relevance of the off-target liver effects of novel anti-atherogenic therapeutic approaches that target macrophage LXR.PMID:38672446 | PMC:PMC11047872 | DOI:10.3390/biom14040429

Source: Atherosclerosis - April 27, 2024 Category: Cardiology Authors: Menno Hoekstra Laura M de Jong Rick van der Geest Lidewij R de Leeuw Rani Krisnamurthi Janine J Geerling Miranda Van Eck Source Type: research